Company intelligence / Profile preview
TorreyPines Therapeutics
La Jolla, California, United Statestorreypinestherapeutics.com ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Other
01
Overview
TorreyPines Therapeutics developed small molecule drugs for central nervous system diseases. Its lead candidate tezampanel showed efficacy in a Phase IIb trial for acute migraine headache. The company also advanced NGX426 and NGX267 into clinical development targeting pain and neurological disorders. In late 2008 it restructured to focus on development only and was acquired by Raptor Pharmaceuticals in 2009[2][3][4].
- Therapeutic areas
- OtherImmunologyNeurologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on TorreyPines Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TorreyPines Therapeutics.